:: Volume 17, Issue 3 (Fall 2007) ::
MEDICAL SCIENCES 2007, 17(3): 139-146 Back to browse issues page
Comparing the efficacy of Avonex, Rebif and Betaferon in motor disability (Expanded Disability Status Scale) and relapsing rate of multiple sclerosis patients
Mehrdokht Mazdeh
, mehrdokhtmazdeh@ yahoo.com
Abstract:   (20144 Views)
Background: Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system (CNS) that is a leading cause of disability in young adults. The aim of the present study was to compare the relative efficacies of Avonex, Rebif and Betaferon in EDSS and relapsing rate in MS patients.
Materials and methods: 126 patients with multiple sclerosis were randomly allocated to the three treatment groups. The first group received Avonex (47.6%), the second group received Rebif (28.5%), and the third group received Betaferon (23.8%). For all patients, first and final EDSS and relapsing rate was assessed.
Results: The mean age of patients was 31.1±8.6 years and 80.2% of patients were female. Differences between mean of first and final EDSS were statistically significant in three groups (p<0.05). The mean of EDSS score changes in Avonex, Betaferon and Rebif groups were 1.38 (31.2%), 1.30(24.3%) and 1.45(30.7%) (NS). In Avonex and Betaferon groups, the difference between attack of MS disease before and after treatment was significant (p<0.05), however, the difference in Rebif group was not significant (NS). The mean decrease relapse of MS disease in Avonex, Betaferon and Rebif groups were 0.69(40.1%), 0.60(42.8%) and 1.25(62.5%) (NS).
Conclusion: Treatment with these three drugs has significantly reduced EDSS score, however, relapsing rate was significantly decreased in Rebif group.
Keywords: Multiple sclerosis, Avonex, Betaferon, Rebif, EDSS(Expanded Disability Status Scale).
Full-Text [PDF 178 kb]   (11667 Downloads)    
Subject: Epidemiology
Received: 2006/09/6 | Published: 2007/09/15

XML   Persian Abstract   Print

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 17, Issue 3 (Fall 2007) Back to browse issues page